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We recently identified osmolyte accumulators as novel biomarkers for chronic skeletal
muscle inflammation and weakness, but their precise involvement in inflammatory
myopathies remains elusive. In the current study, we demonstrate in vitro that, in
myoblasts and myotubes exposed to pro-inflammatory cytokines or increased salt
concentration, mRNA levels of the osmolyte carriers SLC5A3, SLC6A6, SLC6A12,
and AKR1B1 enzyme can be upregulated. Induction of SLC6A12 and AKR1B1 was
confirmed at the protein level using immunofluorescence and Western blotting. Gene
silencing by specific siRNAs revealed that these factors were vital for muscle cells
under hyperosmotic conditions. Pro-inflammatory cytokines activated mitogen-activated
protein kinases, nuclear factor κB as well as nuclear factor of activated T-cells 5 mRNA
expression. In muscle biopsies from patients with polymyositis or sporadic inclusion body
myositis, osmolyte pathway activation was observed in regenerating muscle fibers. In
addition, the osmolyte carriers SLC5A3 and SLC6A12 localized to subsets of immune
cells, most notably to the endomysial macrophages and T-cells. Collectively, this study
unveiled that muscle cells respond to osmotic and inflammatory stress by osmolyte
pathway activation, likely orchestrating general protection of the tissue. Moreover,
pro-inflammatory properties are attributed to SLC5A3 and SLC6A12 in auto-aggressive
macrophages and T-cells in inflamed skeletal muscle.
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INTRODUCTION
The idiopathic inflammatory myopathies represent a diverse group of autoimmune muscle
diseases. The main disease entities recognized today are dermatomyositis (DM), polymyositis
(PM), sporadic inclusion body myositis (IBM), immune-mediated necrotizing myopathy (IMNM),
anti-synthetase syndrome, and unspecific myositis, each of which possess distinct clinical and
myopathological characteristics (1–5). DM patients develop complement-mediated blood vessel
destruction, perimysial inflammation and perifascicular muscle fiber atrophy (6). PM and IBM
are characterized by invasion of nonnecrotic muscle fibers by auto-aggressive cytotoxic T-cells
and macrophages, with inflammation building up mostly at endomysial sites (7). In IBM muscle
fibers, additional degenerative phenomena occur, with rimmed vacuoles and inclusions that contain
aggregates of ectopic proteins (8), a process that is presumed to follow inflammation (9). IMNM
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represents 3 subdivisions according to serologic characteristics:
anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase
myopathy, signal recognition particle myopathy, and myositis-
specific autoantibody negative IMNM (10). Many of the
immunopathogenic mechanisms underlying the inflammatory
myopathies remain poorly understood, hampering the
development of successful therapies that suit the different
patient subtypes.
Muscle is a highly adaptive and dynamic tissue capable of
increasing its mass in response to exercise and of restoring
damage caused by injury via processes that require hypertrophy
and regeneration, respectively. In addition, cells possess a
universal ability to adapt to changing osmotic conditions, a
feature essential for their survival, allowing active anticipation
toward perturbations in volume and disrupted cellular
homeostasis. A complex intracellular mixture of interacting
osmolytes regulates osmotic pressure, which takes shape through
the synthesis and/or import of osmo-active compounds in
cells (11). The solute carrier family (SLC) contains several salt-
dependent membrane transport proteins involved in the selective
import of extracellular constituents: (i) the sodium-myoinositol
cotransporter SLC5A3, (ii) the high-affinity taurine transporter
SLC6A6, and (iii) the betaine and γ-amino-n-butyric acid
(GABA) transporter SLC6A12. AKR1B1 is an aldose reductase
that catalyzes the intracellular conversion of glucose to sorbitol.
In a joint effort, these osmoprotective constituents represent
a universal tool for mammalian cells, and their accumulators
can be ubiquitously expressed throughout human tissues. The
central regulator of osmolyte pathway gene expression is the
transcription factor nuclear factor of activated T-cells 5 (NFAT5),
also termed tonicity enhancer-binding protein (12).
Several observations allowed us to speculate NFAT5-inducible
pathways might be involved in the inflammatory myopathies.
Firstly, the NFAT5 pathway participates in muscle development
and regeneration, by regulating the differentiation of immature
myoblasts to mature multinucleated myotubes (13). NFAT5
levels have been shown to increase in the regenerating fibers
of mice exposed to experimental muscle tissue injury (14),
attributing the transcription factor a role in countering disease-
inflicted muscle tissue damage. Secondly, the NFAT5 pathway
has been firmly linked to nuclear factor κB (NFκB) activity
(15), the latter a key regulator of inflammatory diseases in
general and the inflammatory myopathies in particular (16).
NFAT5 and NFκB share multiple molecular targets (17), many of
which are involved in the immunopathogeneses of inflammatory
Abbreviations: AKR1B1, aldose reductase; DM, dermatomyositis; dMyHC,
developmental myosin heavy chain; ERK, extracellular signal-regulated kinase;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GSK-3α/β, glycogen
synthase kinase 3α/β; HSP70, heat shock protein family of 70kd; IBM, sporadic
inclusion body myositis; IFNγ, Interferon γ; IL1β, Interleukin 1β; IMNM,
immune-mediated necrotizing myopathy; iNOS, inducible nitric oxide synthase;
LTβ, lymphotoxin β; MAPK, mitogen-activated protein kinase; MCP-1, monocyte
chemo-attractant protein-1; MSK2, mitogen- and stress-activated kinase 2;
NFAT5, nuclear factor of activated T-cells 5; NFκB, nuclear factor κB; PM,
polymyositis; siRNA, silencing RNA; SLC5A3, solute carrier sodium-myoinositol
cotransporter; SLC6A6, solute carrier taurine transporter; SLC6A12, solute carrier
betaine and γ-amino-n-butyric acid (GABA) transporter; Th17, Interleukin
17-producing T-cells; TNFα, tumor necrosis factor α.
myopathy including CCL2, also termed monocyte chemo-
attractant protein-1 (MCP-1) (18), lymphotoxin β (LTβ) (19),
tumor necrosis factor α (TNFα) (20), inducible nitric oxide
synthase (iNOS) (21), and heat shock protein family of 70kd
(HSP70) (22). Thirdly, NFAT5-downstream osmolyte pathways
are potent activators of cytotoxic activities of immune cells and
could therefore be implicated in human autoimmune disease.
In addition, dietary salt is determinant to T-cell differentiation,
by direct activation of glycogen synthase kinase 1 (GSK-1) and
subsequent Interleukin 23 receptor stabilization, which enforces
the type 17 helper T-cell (Th17), a T-cell phenotype associated
with autoimmune disease (23).
We recently were the first to describe upregulation of the
osmolyte accumulators SLC5A3, SLC6A6 and AKR1B1 in
muscle tissues from myositis patients (24), and described
NFAT5 expression in myoblasts in culture (25), yet the
precise role osmolyte pathways play in disease mechanisms
remained unexplored. With this study, we aim to substantiate
and functionally connect these biomarkers with muscle
inflammation.We set up in vitromuscle cell models to investigate
osmolyte pathway member expression, using both the human
rhabdomyosarcoma CCL-136 cell line and normal primary
human myotubes. In addition, we investigated their possible
signaling routes, which involves the upstream transcription
factors NFκB and NFAT5, and the mitogen-activated protein
kinases (MAPKs). We confronted this in vitro evidence with
findings in muscle biopsies from patients diagnosed with
inflammatory myopathies.
METHODS
Cell Cultures
Human rhabdomyosarcoma CCL-136 cells (ATCC, Manassas,
VA) were kept in Dulbecco’s modified Eagle medium (DMEM)
supplemented with 10% fetal calf serum (Biochrom, Berlin,
Germany) and 1% L-glutamine (ThermoFisher Scientific,
Waltham, MA). Human muscle cell cultures originated from
muscle biopsies taken from healthy patients needing knee
surgery, obtained with patient consent and approved by the
local ethics committee. Biopsies were minced and trypsinized.
Fragments were seeded in DMEM with pyruvate, high glucose
and L-glutamine, supplemented with penicillin, streptomycin
and 10% fetal calf serum (ThermoFisher Scientific). Cells
were cultured for 2 periods of ∼ 3 weeks during which
CD56+ cells were purified twice with magnetic separation
MiniMACS columns using the supplier’s standard protocol
(Miltenyi Biotec, Bergisch Gladbach, Germany). Myotubes were
obtained by allowing cells to differentiate for approximately
5 days in DMEM medium supplemented with penicillin,
streptomycin and 2% horse serum (ThermoFisher Scientific).
Supplementary Figure S1 illustrates a representative culture of
differentiated myotubes, showing aligned multinucleate muscle
cells. All cells were kept in culture wells or chamber slides at
37◦C in a humified atmosphere containing 5% CO2. Conditions
for cytokine stimulation were as determined earlier (26),
being 30 ng/ml TNFα, 300 u/ml Interferon γ (IFNγ), 20 ng/ml
Interleukin 1β (IL1β) (R and D Systems, Minneapolis, MN), or
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double combinations. Hyperosmotic conditions were created by
supplementing the culture medium with 25–150mM of added
NaCl. Higher concentrations of NaCl lead to complete cell death
within 24 h.
Quantitative Reverse Transcription PCR
RNA was prepared from cells cultured in 12-well culture
plates, using the RNeasy Mini kit and according to the
manufacturer’s specifications (Qiagen, Hilden, Germany).
RNA concentration was measured with a Nanodrop 1000
(ThermoFisher Scientific). cDNA was prepared from 200 ng
of RNA with SuperScript II reverse transcriptase, 500 ng/µl
oligo dTs, 0.1M DTT, and 10mM dNTPs each (Invitrogen,
Darmstadt, Germany). cDNA was quantified through PCR
reaction with Taqman Gene Expression Master mix (Applied
Biosystems, Foster City, CA), using 6-carboxy-fluorescein-
labeled probes and specific primers for: SLC5A3, Hs00272857
_s1; SLC6A6, Hs00161778_m1; SLC6A12, HS00758246_
m1; AKR1B1, Hs00739326_m1; NFAT5, Hs00232437_m1;
MAPK14, Hs01051152_m1; RELA, Hs00153294_m1; NFKB1,
Hs00765730_m1; NFKB2, Hs01028901_g1; glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), Hs99999905_m1 (Applied
Biosystems). Reactions were run in triplicate, following the
standard cycle protocol on a 7500 Real Time PCR System, and
analyzed with software version 2.0.6. (Applied Biosystems).
Data was presented as 11Ct fold-changes compared to the
expression levels in untreated cells, with GAPDH as an internal
housekeeping gene standard.
Immunofluorescent Cytostaining
Cells cultured on glass chamber slides were fixed with ice-
cold acetone and blocked in phosphate buffered saline with
10% bovine serum albumin and 10% goat serum for 1 h
at room temperature. Immunofluorescent detection was
carried out for 1 h at room temperature with commercially
available antibodies: mouse (4µg/ml, sc-514024, SantaCruz
Biotechnology, Santa Cruz, CA) and rabbit (10µg/ml,
nbp188641, Novus Biologicals, Abingdon, UK) anti-SLC6A12;
rabbit (2µg/ml, sc-33219, SantaCruz Biotechnology) and
goat (1µg/ml, sc-17732, SantaCruz Biotechnology) anti-
AKR1B1; mouse anti-developmental myosin heavy chain
(dMyHC) (40µg/ml, RMMy2/9D2, Leica Biosystems, Nussloch,
Germany). The corresponding Alexa594—and Alexa488-labeled
secondary antibodies (ThermoFisher Scientific) were added.
After mounting in Fluoromount G (Southern Biotech, Alabama,
USA), digital photography was performed on a Zeiss Axiophot
microscope (Zeiss, Goettingen, Germany). Pictures were taken
by a cooled CCD digital camera (Retiga 1300, Qimaging,
Burnaby, BC, Canada) and visualized with ImageProPlus
software (MediaCybernetics, Bethesda, MD).
Immunofluorescent Histostaining
For localization studies in muscle tissues, 8µm cryostat
sections were cut from frozen muscle biopsies obtained from
patients without muscle abnormalities (n = 10), inflammatory
myopathies (n = 28), and disease controls diagnosed with
muscular dystrophy (n = 8; for pathological information
consult Supplementary Table S1). Diagnosis of the disease
subgroups PM (n = 4), IBM (n = 9), DM (n = 9), and
IMNM (n = 6) were based upon clinical and myopathological
criteria (27). Diagnosis of PM was reserved to patients with
nonnecrotic invaded muscle fibers present in the biopsy that
had subsequently responded to immunosuppressive therapy.
Sections were fixed in ice-cold acetone and treated with blocking
solution containing 5% donkey serum, 10% heat-inactivated
human serum and 2% bovine serum albumine in phosphate
buffered saline. Incubations with primary antibodies were carried
out in the same solution: 4µg/ml rabbit polyclonal anti-
SLC5A3 (NBP1-02399, Novusbio); 4µg/ml mouse monoclonal
anti-SLC6A6 (E10, SantaCruz Biotechnology); 6µg/ml rabbit
polyclonal anti-SLC6A12 (HPA034973; Merck, Kenilworth,
NJ); 1µg/ml goat polyclonal anti-AKR1B1 (N20, SantaCruz
Biotechnology). Immune cell subtypes and muscle tissue
constituents were visualized through double staining as described
(18). Satellite cells were visualized with goat anti-Pax3/7
(1µg/ml, sc-7748, SantaCruz Biotechnology). To allow double
staining of macrophages with mouse monoclonal antibodies,
FITC labeled anti-CD68 (Agilent, Santa Clara, CA) was
applied. Secondary antibodies were used labeled with CY3
(Jackson ImmunoResearch Laboratories, West Grove, PA) and
AlexaFluor488 (ThermoFisher Scientific). Slides were mounted
with Fluoromount (Southern Biotech) and visualized with a
fluorescence microscope (Zeiss). Conventional semi-quantitative
scoring of staining intensity was performed by three non-blinded
independent observers. Negative control studies consisted
of the omission of primary antibody and the substitution
by non-immune IgGs. Positive control tissues for checking
immunodetection were cultured Hela cells (SLC6A6), frozen
sections containing kidney medulla (SLC5A3, SLC6A12), and
Jurkat cells (AKR1B1).
Western Blotting
Cells cultured in 12-well culture plates were lysed in Ripa
buffer (50mM Tris-HCl, 150mM NaCl, 2.5% Na-deoxycholate,
2.5% NP40, 0.1% sodium dodecyl sulfate pH 7.4) with a
protease inhibitor cocktail added (Roche, Indianapolis, IN)
and centrifuged for 5min at 13000 rpm. The supernatant
was collected and protein concentrations were determined
following a Bradford procedure (Bio-Rad protein assay,
Hercules, CA) with bovine serum albumine standard solutions,
measured in triplicates on the Infinite M200Pro and analyzed
with Magellan 7.2 software (Tecan, Mannedorf, Switzerland).
60 µg protein samples were dissolved in Laemli buffer,
boiled for 2min, separated by 12% sodium dodecyl sulfate-
polyacrylamide gelelectrophoresis, and transferred to a
nitrocellulose membrane (Schleicher and Schuell, Dassel,
Germany). Membranes were blocked with 5% bovine serum
albumine for 1 h at 4◦C and incubated overnight at 4◦C
with 2µg/ml mouse anti-SLC6A12 (sc-514024, SantaCruz
Biotechnology), 4 h at room temperature with 2µg/ml goat
anti-AKR1B1 (sc-17732, SantaCruz Biotechnology), and 1 h
at room temperature with 0.7µg/ml mouse anti-GAPDH
(Sp210-Ag14; Abcam, Cambridge, UK). All incubations were
done in tris-buffered saline buffer containing 0.05% Tween20.
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Appropriate horseradish peroxidase-conjugated secondary
antibodies (Jackson ImmunoResearch, West Grove, PA) were
added for 1 h at room temperature. The chemiluminescent
signal was generated with the Pierce Western blotting substrate
(ThermoFisher Scientific), visualized with the Fusion FX,
and quantified with Vision Capt software, with background
noise filtering using a rolling-ball algorithm (Vilber Lourmat,
Eberhardzell, Germany).
Protein Phosphorylation Profiling
Protein phosphorylation patterns were determined in extracts
obtained from cultured myotubes, using the Proteome Profiler
human phosphor-mitogen activated protein kinase (MAPK)
antibody array according to the manufacturer’s specifications
(Bio-Techne, Abingdon, United Kingdom). Briefly, array
membranes were incubated overnight at 4◦C with lysate
containing 200 µg of cellular protein, detection conditions
were as described in the western blotting section. Protein
densities were quantified, relative to phosphorylated Akt2, as
the calculated mean of duplicate spots per protein, using Image
Studio 5.2 software (Li-Cor Biosciences, Cambridge, UK).
Knockdown Studies
Pools of three target-specific 19–25 nucleotide silencing RNAs
(siRNAs), purchased from SantaCruz Biotechnology, were used:
siRNA SLS5A3 (sc-44516), siRNA SLC6A12 (sc-95904), and
siRNA AKR1B1 (sc-37119). 50% confluent CCL-136 cells and
myotube cultures were changed to 500 µl X-Vivo15 medium
(Sartorius, Goettingen, Germany), to which 3µl of lipofectamine
(ThermoFisher) and 100 nM siRNA had been added. After 5 h,
an extra 200 µl of X-Vivo15 was added, which in treated cells
contained cytokines to a final well concentration of 20 ng/ml
IL1β+300 u/ml IFNγ, or 50mM added NaCl. Cells were
assayed 26 h after addition of the siRNAs. Live and dead cells
were visualized using the ReadyProbes cell viability imaging
blue/green kit (ThermoFisher) according to the manufacturer’s
specifications. Using a fluorescence microscope, a minimum
of 50 cells (blue) was counted per condition, determining the
amount of dead cells (green). Afterwards, cell cultures were
stained with hematoxylin and eosin according to standard
procedures, dehydrated, mounted, and interpreted under a light
microscope. Efficiency of knockdownwas evaluated at themRNA
level using quantitative reverse transcription PCR, following the
method described above. From controls and siRNA-treated CCL-
136 cells seeded in 12-well culture plates, protein samples were
prepared for electrophoresis by adding lithium dodecyl sulfate
sample buffer and reducing agent (Invitrogen, Carlsbad, CA,
USA) and boiling for 3min. Samples were loaded onto 10% bis-
tris gels, with prestained markers alongside to determine the
molecular weight of protein bands. Proteins were transferred
to nitrocellulose membranes by electroblotting, and incubated
with 2µg/ml mouse anti-SLC6A12 (sc-514024), 2µg/ml goat
anti-AKR1B1 (sc-17732), or mouse anti-β actin (sc-47778)
(SantaCruz Biotechnology) for 4 h at room temperature on a
rocking platform. Immunoreaction was visualized using the
chromogenic Western Breeze kit according to the manufacturer’s
specifications (Invitrogen).
Compliance With Ethical Standards
Human experimentation presented in the study was approved
by the Ghent University Hospital Ethics Committee (EC-UZG-
#B670201316956) and adhered to privacy regulations (CBPL-
BEL-#HM003039095). Written informed consent was obtained
from all individual participants included in the study, and all
procedrues were in accordance with the Declaration of Helsinki.
RESULTS
mRNA Quantification in Cultured Muscle
Cells
In CCL-136 cells, expression levels of osmolyte pathway
members were determined in cells treated with pro-inflammatory
cytokines or added NaCl for 24 h (Table 1). In general, a
moderate increase of expression was shown for SLC5A3,
SLC6A6, SLC6A12, and AKR1B1 when cells were treated
with cytokines. The strongest response was a 10-fold increase
of SLC5A3 mRNA expression in IL1β+TNFα-treated cells.
Hyperosmotic conditions also induced osmolyte pathway
expression, with 100mM of added NaCl leading to a 179-fold
increase of SLC6A12, and increasing NFAT5 expression 2.5-fold.
MAPK14 levels were 2-fold increased in both IFNγ+TNFα–
and 50mM NaCl-treated cells. Highest levels of RelA, NFkB1
and NFkB2 could be achieved with pro-inflammatory cytokine
mixtures, though NFkB1 and NFkB2 expression also responded
to added NaCl.
Primary human myotubes treated for 24 h with cytokines or
added NaCl showed induction of osmolyte pathwaymRNA levels
(Table 2). For SLC5A3 and AKR1B1, the strongest induction
could be achieved with added NaCl; SLC6A6 and SLC6A12
were most strongly induced by pro-inflammatory cytokine
mixtures. NFAT5 expression was influenced by both cytokines
and increased salt concentrations, but reached higher expression
levels with IFNγ+IL1β (4,5-fold) than with 125mM NaCl (3-
fold). MAPK14 expression levels were found increased 2-fold
in myotubes treated with IL1β and with 125mM NaCl. The
expression of NFκB subunits was most strongly induced by
treatment with pro-inflammatory cytokines. Nonetheless, 25mM
added NaCl increased NFkB1 expression 8,5-fold. In myotubes
treated for longer periods, added NaCl lead to continuously
increasing SLC5A3, SLC6A12 and AKR1B1 expression levels
over time, culminating in levels all exceeding 200-fold at time
point 72 h (Table 3). In addition, prolonged salt treatment lead
to a time-dependent increase of NFAT5 andMAPK14 expression
levels, reaching a maximum of 9-fold (NFAT5) and 18-fold
(MAPK14). In contrast, the single pulse of pro-inflammatory
cytokines resulted in highest expression levels after 24 h, with
levels nearing normal after 72 h.
Immunofluorescent Protein Localization
Studies in Cultured Muscle Cells
Immunofluorescent staining of CCL-136 cells (Figure 1A)
confirmed the induction of SLC6A12 and AKR1B1 expression
after 24 h of treatment with pro-inflammatory cytokines and
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TABLE 1 | Messenger RNA levels in cultured CCL-136 cells treated for 24 h.
Cytokines Added NaCl
IFNγ IL1β TNFα IFNγ+IL1β IFNγ+TNFα IL1β+TNFα 25 mM 50 mM 75 mM 100 mM
SLC5A3 1 1.1 1.3 2.1 4.6 10.3 0.6 0.5 1.9 3.4
SLC6A6 0.5 0.7 0.8 1.4 1.5 4.3 0.9 1.1 1.2 1.5
SLC6A12 1.7 2 1 3.4 3.8 1.2 1.6 7.7 9 178.7
AKR1B1 1.4 2.3 1.9 1.9 1.6 1.7 1.4 2.1 2.4 5.6
NFAT5 1.1 0.3 0.5 1.4 1.7 1 1.4 4.1 0.8 2.5
MAPK14 0.7 0.8 0.8 1.4 1.9 1.4 1.1 2 0.9 1.3
RELA 0.9 1.2 0.9 1.8 1.7 0.5 0.9 0.8 0.9 1.2
NFkB1 1 1.2 1 6 0.5 3.8 1.5 2.9 1.2 1.9
NFkB2 1.3 1.5 2.7 3.3 12.9 1 1.2 2.3 1.5 1.1
Fold changes compared to untreated cells, normalized to glyceraldehyde 3-phosphate dehydrogenase expression levels, were obtained through quantitative reverse transcription PCR
and calculated as 2−11Ct (mean of three given). Fold changes >2 green; >5 yellow; >10 orange; >100 red.
TABLE 2 | Messenger RNA levels in cultured normal human myotubes treated for 24 h.
Cytokines Added NaCl
IFNγ IL1β TNFα IFNγ+IL1β IFNγ+TNFα IL1β+TNFα 25 mM 50 mM 75 mM 100 mM 125 mM 150 mM
SLC5A3 2.6 5.8 2.5 2.4 1.4 1.9 1.4 2.1 3.6 13 13.9 5
SLC6A6 1.2 1.9 2.9 3.9 2.2 3.1 1.1 1.9 1.8 1.9 1.8 0.4
SLC6A12 21.3 2.1 1.4 177.7 229.2 3.8 2.1 5.9 7.3 32.4 47.9 9.6
AKR1B1 1.5 6.6 3.7 7.5 5.6 4.9 10.7 3.5 4.7 6.9 8.1 2.5
NFAT5 1.4 4.4 1.6 4.5 2.2 2 0.8 1.6 1.3 2.2 3 0.6
MAPK14 1 1.9 1.1 0.6 0.4 0.9 1.4 1.3 1 1.6 1.9 0.6
RELA 2.1 2 1.4 25.3 18.4 4.2 0.8 1.1 1.2 1.1 1.2 0.5
NFkB1 1.5 1.3 0.8 6.8 3.6 2.6 8.7 0.7 0.7 0.6 1.3 0.7
NFkB2 1.2 4.7 2.7 20.5 4 8.4 0.1 1.3 1.2 0.8 1 0.3
Fold changes compared to untreated cells, normalized to glyceraldehyde 3-phosphate dehydrogenase expression levels, were obtained through quantitative reverse transcription PCR
and calculated as 2−11Ct (mean of three given). Fold changes >2 green; >5 yellow; >10 orange; >100 red.
added NaCl at the protein level and showed similar staining
patterns with the two different sets of primary antibodies.
Myotubes immunostaining (Figure 1B) showed increases of
SLC6A12 in response to cytokines at the 48 h time point, with
levels declining again at time point 72 h. For AKR1B1, high
levels were detected following cytokine stimulation from 24 h
onward, compared to the low levels observed in untreated
myotubes. A growth-inhibitory effect of hyperosmotic conditions
was observed in myotubes, which became conspicuous from the
48 h time point on. NaCl-treatment disfavored differentiation
into multinucleate elongated muscle cells, as was assayed
with dMyHC staining (Supplementary Figure S1). Evaluation of
hematoxylin&eosin stains confirmed that salt treatment affected
cell morphology and growth, reducing cell elongation and
disfavoring multinucleate myotubes.
Protein Quantification and Phosphorylation
Patterns of Human Myotubes
SLC6A12 protein levels were below the detection limit in
untreated normal myotubes, but SLC6A12 protein could readily
be shown inmyotubes treated with IL1β+TNFα for 48 h and 72 h
(Figure 2A). SLC6A12 and AKR1B1 protein levels were found to
increase in a time- and dose-dependent manner when myotubes
were exposed to 25 and 50mM of added NaCl (Figure 2B). The
expression levels with the higher doses of NaCl already reached a
maximum at the 48 h time-point (Table 4).
Protein phosphorylation patterns of MAPKs showed that the
strongest signals in the array were the phosphorylated forms
of Akt2 (S474) and heat shock protein 27 (HSP27) (S78, S82)
(Supplementary Figure S2). Akt2 and HSP27 activation was
prominent in untreated and cytokine-treated myotubes alike.
The most notable influence of 24 h IFNγ+IL1β treatment was
an increase in phosphorylation of mitogen- and stress-activated
kinase 2 (MSK2) (S360) 3-fold and MAPK3 (T202, Y204) 2.5-
fold. In addition, levels of phosphorylated glycogen synthase
kinase 3α/β (GSK-3α/β) (S9, S21), MAPK12 (T183, Y185), and
MAPK13 (T180, Y182) were increased 2-fold.
Knockdown Studies in Cultured Muscle
Cells
Both in CCL-136 cells and in primary healthy myotubes, 50mM
of added NaCl decreased cell densities in both siSCL6A12—
and siAKR1B1-treated cells at the 24 h time point, while this
regimen did not harm growth of siSLC5A3-treated muscle
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TABLE 3 | Messenger RNA levels in cultured normal human myotubes treated with cytokines or added NaCl for up to 3 days.
IFNγ+IL1β IFNγ+TNFα 100mM NaCl
24 h 48 h 72 h 24 h 48 h 72 h 24 h 48 h 72 h
SLC5A3 1 0.4 0.2 1 0.6 0.5 10.8 5.8 240.7
SLC6A12 19.1 4.9 1 14.5 13 2.5 43 50.9 2 × 10exp8
AKR1B1 2.4 1.3 0.9 1.7 1.9 1.1 7 27.4 528.8
NFAT5 0.8 0.3 0.04 0.8 0.9 0.3 1.4 3.8 9.4
MAPK14 0.9 0.4 0.3 0.6 0.6 0.6 1.1 1.6 17.8
Fold changes compared to untreated cells, normalized to glyceraldehyde 3-phosphate dehydrogenase expression levels, were obtained through quantitative reverse transcription PCR
and calculated as 2−11Ct (mean of three given). Fold changes >2 green; >5 yellow; >10 orange; >100 red.
FIGURE 1 | Immunofluorescent cytostaining. (A) Staining with mouse anti-SLC6A12 (AlexaFluor 594, red) and rabbit anti-AKR1B1 (AlexaFluor488, green) in CCL-136
cells after 24 h treatment. Untreated control cells shows low levels of SLC6A12 and AKR1B1. Treatment with 30 ng/ml TNFα markedly increases AKR1B1 levels.
Treatment with 300 u/ml IFNγ and 30 ng/ml TNFα strongly increases both SLC6A12 levels and AKR1B1 protein levels. Addition of 100mM NaCl to the medium also
increases both SLC6A12 and AKR1B1 protein expression. (B) Staining with rabbit anti-SLC6A12 (AlexaFluor 488, green) and goat anti-AKR1B1 (AlexaFluor594, red)
in cultured healthy human myotubes at different time points. Myotubes treated with 300 u/ml IFNγ and 30 ng/ml TNFα display low levels of SLC6A12 that is increased
at the 48 h time point. Levels return back to constitutive low levels after 72 h, with staining levels similar to those in untreated cells. Staining for AKR1B1 shows
continuously high levels between 24 and 72 h. In untreated cells, AKR1B1 expression levels are substantially lower. Scale bar = 50 µm.
cells (Figure 3A). Treatment with pro-inflammatory cytokines
on the other hand, combined with knockdown of individual
osmolyte pathway members, did not cause significant effects on
myotube viability, with percentages of dead cells in untreated
vs. cytokine-treated cells respectively: 1% vs. 7% (vehicle), 11%
vs. 25% (siSLC6A12), 33% vs. 15% (siAKR1B1), and 0% vs. 4%
(siSLC5A3). For silencing procedures, efficiency of knockdown
was evaluated in CCL-136 cells (calculated as 1Ct siRNA-
treated cells minus 1Ct of the vehicle control) detecting 16%
(siSLC5A3), 59% (siSLC6A12), and 6% (siAKR1B1) of residual
mRNA expression. Western blotting corroborated efficient
AKR1B1 knockdown at the protein level but did not show a
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FIGURE 2 | Western blotting of protein extracts preepared from cultured normal human myotubes. (A) SLC6A12 and AKR1B1 protein levels in myotubes treated with
cytokine mixtures. SLC6A12 and AKR1B1 proteins are visualized in control cells (C) and in cells treated for 24 h-48 h-72 h with either 300 u/ml IFNγ+30 ng/ml TNFα,
or 20 ng/ml IL1β+30 ng/ml TNFα. SLC6A12 is undetectable in untreated- and in 300 u/ml IFNγ+30 ng/ml TNFα-treated cells, but is induced by treatment with
20 ng/ml IL1β+30 ng/ml TNFα from the 48 h time point on. Low constitutive levels of AKR1B1 in control cells are increased in myotubes treated with both cytokine
mixtures, peaking at the 48 h time point. Relative protein densities of AKR1B1, normalized using glyceraldehyde 3-phosphate dehydrogenase (GAPDH) levels as an
internal standard, have been indicated. (B) SLC6A12 and AKR1B1 protein levels in myotubes treated with added NaCl. Protein bands for SLC6A12 and AKR1B1, and
the internal standard glyceraldehyde 3-phosphate dehydrogenase (GAPDH), are given in an untreated control (C) and in cells treated with different concentrations of
added NaCl. A time-dependent increase is observed in cells treated with 25 and 50mM added NaCl, while more elevated NaCl concentrations show the highest
levels at the 48 h timepoint. The corresponding relative protein densities are listed in Table 4.
substantial reduction of SLC6A12 protein levels (Figure 3B). We
could not quantify SLC5A3 protein in muscle samples using
western blots, as we were unsuccessful in detecting SLC5A3 in the
corresponding positive control samples using rabbit (nbp102399,
NovusBiologicals) and goat (sc-23142, SantaCruz Biotechnology)
antibodies.
Immunolocalization Studies in Muscle
Tissues From Inflammatory Myopathy
Patients
Confirming our earlier descriptive myopathological results
on SLC5A3, SLC6A6, and AKR1B1 expression (24), we
found these factors upregulated in regenerating muscle fibers
present in biopsies in this new cohort of inflammatory
myopathy patients. We now also add SLC6A12 to the
regenerating muscle fiber’s repertory of increased osmolyte
accumulators (Figure 4). High osmolyte pathway member
expression contrasted with the low levels present in muscle
fibers in biopsies from healthy subjects. In tissues from
muscular dystrophy patients, the SLC6A12 muscle fiber
staining pattern was similar to inflammatory myopathies,
with diffuse staining mostly in small regenerating CD56
positive muscle fibers and discontinuous sarcolemmal
staining in subsets of CD56 negative muscle fibers
(Supplementary Figure S3). We verified that this did not
represent adjacent satellite cells and observed no co-localization
with Pax3/7 staining.
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TABLE 4 | Protein densities in cultured normal human myotubes treated with added NaCl for varying periods of time.
Untreated 25mM NaCl 50mM NaCl 75mM NaCl 100mM NaCl
24 h 48 h 72 h 24 h 48 h 72 h 24 h 48 h 72 h 24 h 48 h 72 h
SLC6A12 0.001 0.097 0.264 0.297 0.139 0.180 0.198 0.154 0.217 0.131 0.112 0.115 0.094
AKR1B1 0.192 0.202 0.210 0.347 0.336 0.377 0.437 0.281 0.436 0.347 0.209 0.278 0.263
Protein densities of western blots (shown in Figure 2) were normalized using glyceraldehyde 3-phosphate dehydrogenase levels. Highest protein expression levels per time point have
been highlighted.
FIGURE 3 | Knockdown studies. (A) Hematoxylin&Eosin staining of CCL-136 and healthy human myotube cultures treated with silencing RNAs. Representative
images are shown of cell cultures exposed to 300 u/ml IFNγ+20 ng/ml IL1β or to 50mM of added NaCl. Culture densities decrease substantially in siSLC6A12- and
siAKR1B1-treated cultures challenged with 50mM of added NaCl, both in CCL-136 cells and in normal human myotubes. Addition of siSLC5A3 does not apparently
inhibit cell growth, only resulting in mildly reduced densities of CCL-136 cells which could equally be observed in controls treated with 50mM NaCl.
Scale bar = 100µm. (B) Western blots visualizing SLC6A12 and AKR1B1 protein in CCL-136 cells treated with silencing RNAs. The severe reduction of the AKR1B1
protein band in siAKR1B1-treated cells (arrow) shows the efficiency of expression knockdown. C represents the control sample, and equal loading is shown by β-actin
protein bands.
SLC5A3 and SLC6A12 were expressed by inflammatory
cells in inflammatory myopathy muscle biopsies (Figure 4).
SLC6A12 was detected in subsets of the endomysial CD68+
cells surrounding muscle fibers in PM and IBM tissues. In
comparison, only a small minority of tissue-infiltrating CD68+
cells in DM and in muscular dystrophy tissues were SLC6A12
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FIGURE 4 | Immunofluorescent histostaining. Staining of SLC6A12 and AKR1B1 in muscle sections from patients diagnosed with inflammatory myopathy.
Polymyositis (PM): A subset of CD68+ cells (AlexaFluor488, green), representing mostly M1 phenotype macrophages, express SLC5A3 and SLC6A12 (CY3, red).
Dermatomyositis (DM): Two small regenerating muscle fibers (arrows), identified as strongly positive for CD56 (AlexaFluor488, green), express high levels of SLC6A12
protein (CY3, red). Scale bar =50 µm.
positive, and the more sparse inflammatory cells observed in
IMNM tissues were SLC6A12 negative. SLC6A12 was rarely
observed in the CD8+ T-cells of PM and IBM tissues. SLC5A3 on
the other hand, could be detected in a substantial part of CD3+
T-cells, with most non-invading CD8+ T-cells being negative
while CD8+ cells actively invading nonnecrotic muscle fibers
in PM and IBM were often strongly positive. The majority of
CD68+ cells, and part of the CD206+ cells were also SLC5A3
positive. In contrast, inflammatory cells were invariably AKR1B1
and SLC6A6 negative in all muscle tissues tested.
DISCUSSION
Our earlier studies had identified osmolyte pathway members
as biomarkers for inflammatory myopathies, yet the pathogenic
routes behind their elevated expression remained unknown. The
present study offers further context and allows us to speculate on
the underlying mechanisms.
Inflammatory Stress Induces Osmolyte
Pathways in Muscle Cells
We here report that, in addition to increased NaCl
concentrations, pro-inflammatory cytokines can induce
osmolyte pathways in muscle cells in an in vitro setting. In
response to osmotic stress, normal primary myotubes displayed a
continuous increase of SLC5A3, SLC6A12, and AKR1B1 mRNA
expression levels over time, while single cytokine pulse led to
highest mRNA levels after 24 h, steadily decreasing afterwards
and returning to near-normal levels at the 72 h time point.
Immunocytochemical staining and western blotting experiments
confirmed the transient induction pattern of SLC6A12 at the
protein level. We cannot rule out fast cytokine degradation
in the culture medium, yet this is unlikely as many have
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reported prolonged effects by single pulse cytokine treatments
over several days (28–30). Using silencing techniques, we
showed that compromising osmolyte accumulator expression
negatively influenced cell growth only when muscle cells faced
hyperosmotic conditions. We produced strongest evidence for
AKR1B1, for which the knockdown regimen severely reduced
AKR1B1 protein levels, yet did not compromise growth when
myoblasts and myotubes were challenged with pro-inflammatory
cytokines. Based upon this data, we speculate on different
levels of importance of the osmolyte pathway dependent upon
the challenges muscle cells face: osmolytes being essential
protectors against osmotic stress while having a less vital yet
regulatory role in the response to inflammatory stress. Our
observations would need to be confirmed and analyzed further
with knockdown combinations, as an important additional
facet is the degree of redundancy of function displayed by the
different osmolyte pathway members. In evidence, only SLC5A3
deficiency represents a lethal murine phenotype (31), with
knockout of AKR1B1, SLC6A6, and SLC6A12 resulting in viable
mice suffering from limited defects in renal function (32–34).
The compensatory role of remaining osmolytes when activity
of single pathway members is compromised, has long been
confirmed in kidney cells (35).
Transcription factors NFκB and NFAT5 represent key
regulators of cell’s responses to inflammatory stress on the one
hand and osmotic stress on the other hand. Not surprisingly
therefore, pro-inflammatory cytokines were the most potent
inducers of RelA, NFkB1, NFkB2 expression in muscle cells.
However, we did observe some effects of NaCl-treatment on
NFκB expression levels and, vice versa, NFAT5 expression
responded to pro-inflammatory cytokines. Thus, muscle cells’
responses to inflammatory and osmotic stress appear not
separately regulated via NFκB and NFAT5, respectively.
The MAP kinases, a large family of Ser/Thr kinases that
translate cell surface signals to the nucleus, play a crucial role
in inflammation (36), which led us to study their involvement
in muscle cells’ responses to pro-inflammatory cytokines. We
found Akt2 and HSP27 were most heavily phosphorylated
in myotube cultures, but their activation was unaltered in
response to inflammatory cytokines. Akt signaling influences
muscle development and regeneration, affecting either initiation
(Akt1) or maturation (Akt2) of myotubes (37). HSP27 is also
associated with myotube differentiation and was found absent
from myoblasts (38). The strong activation of Akt2 and HSP27
we observed in our in vitromodel fits with the differentiated stage
of the myotubes we studied in our experiments. The MAPKs of
the p38 subgroup have been put forward as complex regulators
of osmolyte pathways, through their hypertonicity-induced
phosphorylation, and have been implicated in inflammatory
disease (39). Our study found MAPK14 mRNA expression
increased up to 2-fold by pro-inflammatory cytokines, and we
observe increased phosphorylation of MAPK12 and MAPK13
in human primary myotubes treated for 24 h with IL1β+IFNγ.
Of the extracellular signal-regulated kinases (ERK) on the other
hand, we observed increased phosphorylation ofMAPK3 (ERK1)
in IL-1β+IFN-γ-treated myotubes. This is in line with our recent
study that showed cytokines induce ERK1/2 phosphorylation,
which subsequently leads to protein deposition and autophagy
in muscle cell cultures (40). We propose that the 24 h response
of muscle cells to pro-inflammatory cytokines may thus be
regulated primarily via such phosphorylation-driven activation
of residential MAPKs. Muscle cells exposed to osmotic stress
for prolonged periods appear to require extra measures for
their protection, culminating in 18-fold (MAPK14) and 9-fold
(NFAT5) increases in expression levels.
Osmolyte Pathways Are Activated in
Regenerating Muscle Cells
Osmolytes are known regulators of skeletal muscle development,
with the involvement of taurine and betaine already described
in most detail. Taurine is essential for skeletal muscle buildup,
and knockout mice lacking its transporter SLC6A6 display
severe structural defects (41) and exercise intolerance (42).
The trimethylglycine betaine appears also important for proper
muscle functioning, although SLC6A12 knockout mice have
been reported to develop only mild myopathy (34). Betaine
promotes muscle fiber differentiation and myotube size (43) via
stimulation of the mechanistic target of rapamycin pathway (44)
and disturbed osmolyte balances have been implicated in muscle
disease. Taurine levels were significantly reduced in muscle from
myositis patients compared to healthy controls (45), while in
urine on the other hand both taurine and betaine levels were
increased in patients (46). In the murine Duchenne muscular
dystrophy model, taurine content of muscle was low, mostly
early in disease progression, and a reduction of its transporter
SLC6A6 was observed (47). Yet, in the canine golden retriever
muscular dystrophy model, muscle levels of taurine and SLC6A6
were 1.5- and 20-fold increased (48) compared to healthy
dogs, pointing to possible differences between species and/or
at different disease stages. Our localization studies revealed
strong increases of osmolyte accumulators in small regenerating
fibers. Possibly, protein replacement and refolding during the
regeneration process are chaperoned by osmolytes, the latter
aiding protection of functional protein conformations (49).
Subsets of Muscle-Infiltrating
Inflammatory Cells Express SLC5A3 and
SLC6A12
In addition to the muscle cells’ general and dynamic repertory
of osmolyte accumulators, we found two osmolyte pathway
members, SLC5A3 and SLC6A12, selectively expressed in
subsets of macrophages and T-cells infiltrating skeletal muscle.
Interestingly, we observed an association with active invasion
of nonnecrotic muscle fibers, a phenomenon typically observed
in PM and IBM muscle tissues (50), which fits with current
notions of how osmolytes behave as potent cytotoxic regulators.
Cytotoxic macrophages have been shown to accumulate betaine,
myoinositol and taurine as compatible organic osmolytes in
response to osmotic stress, via MAPK-regulated upregulation
of osmolyte transporters (51, 52). It is well known that
macrophages have versatile functionalities, with a spectrum
stretching out between the classical inflammatory M1 phenotype,
to the alternative anti-inflammatory, tissue repair-oriented
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M2 phenotype (53). Significantly higher levels of AKR1B1
mRNA and protein have been reported in M1 macrophages
compared with M2-polarized macrophages (54). The upstream
transcription factor NFAT5 is enhanced by the M1-promoting
pro-inflammatory and hypoxic conditions associated with
autoimmune diseases, which is particularly suggested to regulate
the chemokine MCP-1 and subsequent synovial macrophage
survival in rheumatoid arthritis (55). We found a subset of
CD68+ cells, regarded as representing mostly M1 macrophages,
to express SLC5A3 and SLC6A12, most prominently in PM
and IBM tissues. In addition to macrophages, T-cells have
also been shown to engage NFAT5-regulated pathways in their
development and activation (56) and, in accordance, we found
SLC5A3 and SLC6A12 expression in a minority of T-cells. In
helper T-cells (Th-cells), salt-induced NFAT5 activity promotes
their differentiation into Interleukin 17-producing Th-cells
(Th17-cells) (57). This is relevant to inflammatory myopathy, as
IL-17 induces and maintains chronic inflammation, and Th17-
cells represent a pathogenic subset of T-cells associated with
inflammatory myopathy (58).
CONCLUSIONS
The expression of osmolyte pathway members extends to human
tissues that normally are not exposed to hypertonicity, which has
led to the assumption that these factors have additional more
versatile functions. In this respect, they have been put forward
as biomarkers for inflammation (59) and tumor metastasis (60).
The data we presented here points to a general role for osmolyte
accumulation, via AKR1B1, SLC5A3, SLC6A6, and SLC6A12
upregulation, in muscle cells challenged by inflammatory stress,
presumably in an attempt to stabilize protein function in sight
of the changed proteome during regeneration. In addition, our
data suggest an individual inflammatory role for SLC5A3 and
SLC6A12 as potential regulators of the myocytotoxicity displayed
by muscle tissue-infiltrating auto-aggressive immune cells. The
data we offer further adds to the complexity of inflammatory
myopathy immunopathogeneses, broadening our understanding
of this heterogeneous group of diseases.
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